Microdosing for ADHD: What the Research Shows

The Complex Relationship Between ADHD and Depression

Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. It is often accompanied by co-occurring mental health conditions, with depression being one of the most prevalent. Approximately 50% of adults with ADHD also experience a depressive disorder [Haijen et al., 2022]. This significant overlap is not coincidental; both conditions involve dysregulation within key brain networks, particularly the default mode network (DMN), and often present with difficulties in emotional regulation. Both ADHD and depression have also been shown to respond to interventions that promote neuroplasticity, the brain's ability to reorganize itself by forming new neural connections [Haijen et al., 2024]. The shared underlying mechanisms suggest that treatments targeting these common pathways could be beneficial for both conditions.

Insights from Microdosing Surveys

The growing interest in microdosing psychedelics for mental health conditions has led to several large-scale surveys exploring user experiences. A notable 2019 survey involving 1,116 microdosers identified ADHD as the second most common reason for engaging in microdosing, trailing only depression [Hutten et al., 2019a]. This indicates a significant self-medication trend among individuals with ADHD seeking alternative approaches to symptom management. Further substantiating this, a 2021 survey specifically focused on microdosing for ADHD reported compelling subjective improvements: 80% of participants claimed enhanced focus and concentration, while 67% noted a reduction in impulsivity [Haijen et al., 2022]. These self-reported benefits, while not clinical evidence, highlight a perceived positive impact on core ADHD symptoms and emotional well-being.

The Proposed Neurological Mechanism: Modulating the Default Mode Network

The default mode network (DMN) is a brain network that is active when an individual is not focused on the outside world and the brain is at wakeful rest. In both ADHD and depression, the DMN is often found to be overactive or dysregulated. In ADHD, an overactive DMN can manifest as excessive mind-wandering, difficulty sustaining attention, and intrusive thoughts, contributing to the characteristic symptoms of inattention and distractibility. Psilocybin, the active compound in certain psychedelic mushrooms, has been shown to reduce the rigidity and overactivity of the DMN [Carhart-Harris et al., 2012]. By dampening this network's dominance, psilocybin may allow for greater cognitive flexibility and improved attentional control, potentially explaining its reported benefits in both ADHD and depressive symptoms. This modulation of the DMN is a key area of ongoing research into the therapeutic potential of psychedelics.

Microdosing and Conventional ADHD Medication: Considerations and Interactions

Many individuals with ADHD rely on conventional stimulant medications (e.g., methylphenidate, amphetamines) or non-stimulants (e.g., atomoxetine) to manage their symptoms. When considering microdosing alongside these treatments, it's crucial to understand potential interactions. Currently, there are no documented dangerous interactions between psilocybin at microdosing doses and stimulant medications [Haijen et al., 2022]. However, both stimulants and psilocybin influence neurotransmitter systems, particularly serotonin and dopamine. Combining them can, for some individuals, lead to feelings of overstimulation, anxiety, or discomfort. Therefore, a cautious approach is recommended. Starting microdosing on a day when conventional stimulants are not taken is a reasonable strategy to assess individual sensitivity and avoid potential synergistic overstimulation. Any decision to combine microdosing with prescribed medication should be made in consultation with a healthcare provider.

The Role of Neuroplasticity in ADHD Treatment

Neuroplasticity, the brain's ability to form and reorganize synaptic connections, is a fundamental process underlying learning, memory, and recovery from brain injury. In the context of ADHD, impaired neuroplasticity may contribute to the difficulties in cognitive flexibility and behavioral adaptation. Psychedelics, including psilocybin, are increasingly recognized for their potential to enhance neuroplasticity [Ly et al., 2018]. Studies suggest that psilocybin can promote the growth of new neural connections and increase synaptic density, particularly in areas of the brain associated with mood and cognition. This enhanced neuroplasticity could provide a biological basis for the observed improvements in focus, emotional regulation, and cognitive function reported by microdosers with ADHD. By fostering new connections and pathways that can lead to improved cognitive function and emotional resilience [NPR, 2024]. This mechanism is particularly relevant for ADHD, where enhancing brain flexibility could help individuals overcome rigid thought patterns and improve executive functions.

Research Findings: Impact on ADHD Symptoms and Well-being

Several studies have investigated the effects of microdosing on ADHD symptoms and overall well-being. A prospective naturalistic study by Haijen et al. (2022) found significant decreases in self-reported ADHD symptoms after two weeks of microdosing, with further reductions observed at four weeks. The study utilized the Conner's Adult ADHD Rating Scale (CAARS-S:SV) and reported that mean CAARS-S:SV T-scores were significantly lower at two weeks (Δ2W–0W = −10.17, p < .001) and four weeks (Δ4W–0W = −15.43, p < .001) compared to baseline. These improvements were seen across various subscales, including inattention and hyperactivity/impulsivity [Haijen et al., 2022].

Table 1: Changes in CAARS-S:SV Subscale T-Scores After Microdosing

Data adapted from Haijen et al., 2022 [Haijen et al., 2022].

Beyond symptom reduction, the study also reported significant increases in well-being, as measured by the World Health Organisation-Five Well-Being Index (WHO-5). Well-being scores were significantly higher at two weeks (Δ2W–0W = 16.47, p < .001) and four weeks (Δ4W–0W = 17.80, p < .001) after microdosing compared to baseline. Interestingly, the study found a moderate negative correlation between changes in ADHD symptoms and well-being, suggesting that as ADHD symptoms decreased, well-being improved [Haijen et al., 2022]. This indicates a holistic positive impact of microdosing on the mental health of individuals with ADHD.

Emotion Regulation and Empathy

Another study by Haijen et al. (2024) specifically investigated the effects of psychedelic microdosing on emotion regulation (ER) and empathy in adults with severe ADHD symptoms. The study found improvements in self-reported ER, with increased cognitive reappraisal (CR) scores at 2 and 4 weeks and decreased expressive suppression (ES) scores at 4 weeks compared to baseline. Cognitive reappraisal, the ability to reinterpret an emotion-eliciting event, showed a significant main effect of time (F(2, 132.0) = 4.29, p = .016, ηp² = 0.06), with CR scores significantly higher at 2W (Δ2W–0W = 2.08, p = .013) and 4W (Δ4W–0W = 2.47, p = .011) compared to baseline [Haijen et al., 2024]. Expressive suppression, the inhibition of emotional expression, showed a significant main effect of time (F(2, 123.8) = 4.20, p = .017, ηp² = 0.06), with ES scores significantly lower at 4W compared to baseline (Δ4W–0W = −2.01, p = .002) [Haijen et al., 2024].

Regarding empathy, aspects of cognitive empathy (perspective-taking) and emotional empathy (personal distress) were enhanced, while other aspects (fantasy and empathic concern) remained unchanged. Perspective-taking scores were significantly higher at 4W compared to baseline (Δ4W–0W = 1.92, p < .001) [Haijen et al., 2024]. Personal distress scores were lower at 2W compared to baseline (Δ2W–0W = −1.09, p = .046) [Haijen et al., 2024]. These findings suggest that microdosing may not only alleviate core ADHD symptoms but also improve emotional processing and social cognition, which are often challenging for individuals with ADHD.

Comparing Microdosing to Conventional ADHD Medication

The Haijen et al. (2024) study also included a comparison between individuals microdosing without conventional ADHD medication and those using conventional ADHD medication (treatment-as-usual, TAU). The results indicated that adults with severe ADHD symptoms experienced reduced ADHD symptoms through microdosing, evidenced by lower symptom severity after 4 weeks compared to conventional medication users. Specifically, the microdosing group showed lower T-scores on all CAARS-S:SV subscales (inattention, hyperactivity/impulsivity, DSM-IV total symptoms, and ADHD index) at 4 weeks compared to the TAU group. Furthermore, the microdosing group scored below the clinically elevated symptoms threshold on all subscales, whereas the medication group scored below this threshold on only one subscale [Haijen et al., 2024]. This suggests that microdosing could be an effective alternative or complementary treatment for ADHD, potentially offering broader benefits than conventional medications alone, particularly in areas like emotion regulation.

The Importance of Dosage and Substance

The effectiveness of microdosing can be influenced by the substance used and the dosage. The Haijen et al. (2022) study reported that the majority of participants (78%) used psilocybin/psilocin (magic mushrooms, truffles) for microdosing, followed by novel lysergamides (12%) and LSD (9.5%). The average self-reported doses were 722 mg (SD: 485.5) for psilocybin/psilocin, 17.5 μg (SD: 31.1) for novel lysergamides, and 12 μg (SD: 6.4) for LSD [Haijen et al., 2022]. These variations highlight the need for more controlled studies to determine optimal dosages and substances for specific therapeutic outcomes in ADHD. The brand Shrooomz is committed to exploring and providing high-quality functional mushroom products, and while psilocybin is not currently legal in all regions, understanding its potential benefits through research is crucial for future developments. Secret Shrooomz believes in supporting research that can lead to safe and effective solutions for mental health.

Limitations and Future Research

While the findings on microdosing for ADHD are promising, it is important to acknowledge the limitations of current research. Many studies, including those discussed, are naturalistic and observational, meaning participants self-selected to microdose and were not blinded or randomized. This can introduce biases, such as the placebo effect, where positive expectations can influence perceived outcomes [Geers and Rose, 2011]. The Haijen et al. (2022) study noted a significant dropout rate, with only 20% of participants completing the four-week follow-up, which could further bias results towards those with positive experiences. Future research needs to include rigorous placebo-controlled, double-blind randomized clinical trials to definitively establish the efficacy and safety of microdosing for ADHD. Additionally, more research is needed to understand the long-term effects, optimal dosing protocols, and potential interactions with other medications. The current research also highlights the need for updated ADHD assessment scales that align with DSM-5 criteria, as some older scales may not fully capture the nuances of adult ADHD [Haijen et al., 2022].

Internal Links

• Microdosing Mushrooms for Depression
• Microdosing Mushrooms for Anxiety
• Psilocybin PTSD Research
• Microdosing vs. Antidepressants Side Effects
• Psilocybin Neuroplasticity: How Mushrooms Rewire the Brain

Frequently Asked Questions (FAQ)

Q: Is microdosing psilocybin legal for ADHD treatment?

A: The legality of psilocybin varies significantly by region. In most places, psilocybin remains a controlled substance and is illegal. While research is ongoing, it is not yet an approved treatment for ADHD. Always check local laws and regulations and consult with a healthcare professional.

Q: How does microdosing psilocybin compare to traditional ADHD medications?

A: Preliminary research suggests that microdosing psilocybin may offer benefits for ADHD symptoms and emotion regulation, potentially even outperforming conventional medications in some aspects, as indicated by studies comparing microdosing groups to treatment-as-usual groups [Haijen et al., 2024]. However, more rigorous clinical trials are needed to draw definitive conclusions. Traditional ADHD medications have established efficacy and safety profiles.

Q: What are the potential side effects of microdosing for ADHD?

A: While microdosing is generally considered to have fewer side effects than full psychedelic doses, some individuals may experience mild anxiety, restlessness, or difficulty sleeping. It is crucial to start with a very low dose and monitor your reactions. Combining microdosing with stimulant medications can potentially lead to overstimulation, so caution and medical consultation are advised.

Q: Can microdosing improve focus and concentration in individuals with ADHD?

A: Many anecdotal reports and survey studies suggest that microdosing can improve focus and concentration in individuals with ADHD. For example, a 2021 survey found that 80% of ADHD microdosers reported improvements in these areas [Haijen et al., 2022]. The proposed mechanism involves the modulation of the default mode network and enhanced neuroplasticity, which could contribute to better attentional control.

Q: Where can I find more information about microdosing research?

A: Reputable scientific journals, university research centers, and organizations dedicated to psychedelic research are excellent sources of information. Always look for peer-reviewed studies and consult with medical professionals for personalized advice. You can also explore the Shrooomz Research Hub for curated information on functional mushrooms and microdosing.

Conclusion

The landscape of ADHD treatment is continuously evolving, with growing interest in alternative and complementary therapies like psychedelic microdosing. While conventional medications remain a cornerstone of treatment for many, the emerging body of research on microdosing psilocybin for ADHD presents a compelling narrative. Studies suggest potential benefits in reducing core ADHD symptoms, improving emotional regulation, and enhancing overall well-being. The proposed mechanisms, particularly the modulation of the default mode network and the promotion of neuroplasticity, offer a scientific basis for these observed effects. However, it is crucial to approach microdosing with caution and an understanding of its current research status. The naturalistic and observational nature of many studies highlights the need for more rigorous, placebo-controlled clinical trials to establish definitive efficacy, optimal dosages, and long-term safety. As the scientific community continues to explore the therapeutic potential of psychedelics, individuals considering microdosing for ADHD should engage in informed decision-making, ideally in consultation with healthcare professionals. The journey towards comprehensive and personalized ADHD care may well include innovative approaches like microdosing, offering new avenues for improved quality of life.

References

[Haijen et al., 2022] Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2022). Microdosing with psychedelics to self-medicate for ADHD symptoms in adults: A prospective naturalistic study. Neuroscience Applied, 1, 101012. https://pmc.ncbi.nlm.nih.gov/articles/PMC12244228/

[Haijen et al., 2024] Haijen, E. C. H. M., Hurks, P. P. M., & Kuypers, K. P. C. (2024). Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation, empathy, and ADHD symptoms in adults with severe ADHD symptoms: A naturalistic prospective comparison study. European Psychiatry, 67(1), e18. https://pmc.ncbi.nlm.nih.gov/articles/PMC10966614/

[Hutten et al., 2019a] Hutten, N. R. P. W., Mason, N. L., & Kuypers, K. P. C. (2019a). Self-medication with psychedelics: A survey study. Journal of Psychopharmacology, 33(11), 1371-1380.

[Geers and Rose, 2011] Geers, A. L., & Rose, J. P. (2011). The psychology of placebo effects. Psychology & Health, 26(11), 1427-1439.

[NPR, 2024] This is your brain on drugs: How psilocybin can trigger brain plasticity. (2024, July 18). NPR. https://www.npr.org/sections/shots-health-news/2024/07/18/g-s1-11501/psilocybin-psychedelic-drug-brain-plasticity-depression-addiction

[Carhart-Harris et al., 2012] Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Evans, L., Thase, A. M., ... & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138-2143.

[Ly et al., 2018] Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, E. D., ... & Olson, D. E. (2018). Psychedelics promote structural and functional neuroplasticity. Cell Reports, 23(11), 3170-3182.

[Szigeti et al., 2021] Szigeti, B., Rácz, A., Rácz, B., & Carhart-Harris, R. L. (2021). Self-blinding citizen science to investigate psychedelic microdosing. eLife, 10, e67855.